longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

XJZY

002332

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 22.40, within the reasonable range, cheaper than 33.67% of the time in the past 3 years, and the industry ranks 52/221, the industry Median 23.24.

22.4xP/E
¥8.74Stock price
¥0.39Earnings per share
22.4xP/E
Stock price¥8.74Earnings per share¥0.39

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
20.57x
Typical range
16.09x–27.32x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.24x
020406080

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.24x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
600276SHHengrui Pharma
39.27x17.99%¥303.45B
002422SZKELUN PHARMA
36.53x15.33%¥66.81B
600085SHTRT
33.45x7.45%¥32.45B
000739SZAPELOA
32.71x23.79%¥27.80B
600329SHDRTG
31.87x51.62%¥27.03B
600521SHHuahaipharm
39.52x305.56%¥24.81B
002262SZNHWA
20.16x14.76%¥22.12B
605507SHGuobang Pharma
20.22x--¥14.29B
603456SHJiuzhou Pharma
24.14x12.93%¥14.28B
603707SHNKF
26.57x11.11%¥12.83B
002019SZYifan Pharmaceutical
38.45x12.12%¥11.67B
600420SHSHYNDEC
20.67x--¥11.27B
600572SHCONBA
22.00x--¥10.97B
300357SZWolwo Pharma
25.33x18.88%¥10.57B
002626SZKingdomway
38.92x56.36%¥10.22B
688513SHEASTON BIOPHARMACEUTICALS
32.63x0.00%¥9.05B
688076SHSinopep
38.08x91.51%¥9.04B
300401SZGARDEN BIOPHARMA
32.44x56.86%¥8.93B
002332SZXJZY
22.40x5.56%¥8.65B
002437SZGLORIA PHARMA.
21.00x--¥8.43B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.